- Report
- February 2024
- 175 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- January 2024
- 120 Pages
Global
From €7636EUR$7,950USD£6,574GBP
- Report
- March 2024
- 188 Pages
Global
From €3241EUR$3,374USD£2,790GBP
€3601EUR$3,749USD£3,100GBP
- Report
- March 2024
- 186 Pages
Global
From €3241EUR$3,374USD£2,790GBP
€3601EUR$3,749USD£3,100GBP
- Report
- March 2024
- 196 Pages
Global
From €3241EUR$3,374USD£2,790GBP
€3601EUR$3,749USD£3,100GBP
- Report
- March 2024
- 187 Pages
Global
From €3241EUR$3,374USD£2,790GBP
€3601EUR$3,749USD£3,100GBP
- Report
- January 2024
- 120 Pages
Global
From €5715EUR$5,950USD£4,920GBP
- Report
- October 2023
- 150 Pages
Global
From €5715EUR$5,950USD£4,920GBP
- Report
- January 2024
- 200 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- February 2024
- 250 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- January 2024
- 175 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- January 2024
- 200 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- January 2024
- 244 Pages
Global
From €4802EUR$5,000USD£4,134GBP
- Report
- May 2024
- 146 Pages
Global
From €5235EUR$5,450USD£4,507GBP
- Report
- November 2023
- 139 Pages
Global
From €2400EUR$2,499USD£2,066GBP
- Report
- November 2023
- 181 Pages
Global
From €4706EUR$4,900USD£4,052GBP
- Report
- October 2023
- 190 Pages
Global
From €4706EUR$4,900USD£4,052GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2401EUR$2,500USD£2,067GBP
The JAK Inhibitor market is a subset of the larger Immune Disorders Drugs market. JAK Inhibitors are a type of drug used to treat a variety of immune-related disorders, such as rheumatoid arthritis, psoriasis, and Crohn's disease. These drugs work by blocking the activity of Janus kinase (JAK) enzymes, which are involved in the body's inflammatory response. JAK Inhibitors are typically taken orally, and are often used in combination with other medications.
The JAK Inhibitor market is highly competitive, with a number of large pharmaceutical companies vying for market share. Some of the major players in the market include AbbVie, Pfizer, Novartis, and Johnson & Johnson. Other companies, such as Celgene, Merck, and Eli Lilly, are also active in the market. Show Less Read more